JP2015017143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015017143A5 JP2015017143A5 JP2014221571A JP2014221571A JP2015017143A5 JP 2015017143 A5 JP2015017143 A5 JP 2015017143A5 JP 2014221571 A JP2014221571 A JP 2014221571A JP 2014221571 A JP2014221571 A JP 2014221571A JP 2015017143 A5 JP2015017143 A5 JP 2015017143A5
- Authority
- JP
- Japan
- Prior art keywords
- delivery device
- osmotic delivery
- osmotic
- peptide
- reservoir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003204 osmotic effect Effects 0.000 claims 40
- 239000000203 mixture Substances 0.000 claims 11
- 239000000725 suspension Substances 0.000 claims 11
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 235000018102 proteins Nutrition 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 238000009472 formulation Methods 0.000 claims 8
- 229920000642 polymer Polymers 0.000 claims 7
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- 238000013268 sustained release Methods 0.000 claims 6
- 239000012730 sustained-release form Substances 0.000 claims 6
- 108010011459 Exenatide Proteins 0.000 claims 5
- 229940123993 Incretin mimetic Drugs 0.000 claims 5
- 229960002903 benzyl benzoate Drugs 0.000 claims 5
- 229960001519 exenatide Drugs 0.000 claims 5
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 4
- 230000003078 antioxidant effect Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 3
- 229930006000 Sucrose Natural products 0.000 claims 3
- 150000001720 carbohydrates Chemical class 0.000 claims 3
- 150000002016 disaccharides Chemical class 0.000 claims 3
- 239000004615 ingredient Substances 0.000 claims 3
- 229930182817 methionine Natural products 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 claims 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- 108010088847 Peptide YY Proteins 0.000 claims 2
- 102100029909 Peptide YY Human genes 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 238000009792 diffusion process Methods 0.000 claims 2
- 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 102400001368 Epidermal growth factor Human genes 0.000 claims 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 1
- 102000002265 Human Growth Hormone Human genes 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 claims 1
- 239000000854 Human Growth Hormone Substances 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 101800001388 Oxyntomodulin Proteins 0.000 claims 1
- 102400000319 Oxyntomodulin Human genes 0.000 claims 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 229940126864 fibroblast growth factor Drugs 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 239000002357 osmotic agent Substances 0.000 claims 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 239000002356 single layer Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19627708P | 2008-10-15 | 2008-10-15 | |
| US61/196,277 | 2008-10-15 | ||
| US20471409P | 2009-01-09 | 2009-01-09 | |
| US61/204,714 | 2009-01-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532079A Division JP5643762B2 (ja) | 2008-10-15 | 2009-10-14 | 高濃度薬物粒子、製剤、懸濁液、及びこれらの使用 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015100271A Division JP2015143286A (ja) | 2008-10-15 | 2015-05-15 | 高濃度薬物粒子、製剤、懸濁液、及びこれらの使用 |
| JP2017058941A Division JP2017119709A (ja) | 2008-10-15 | 2017-03-24 | 高濃度薬物粒子、製剤、懸濁液、及びこれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015017143A JP2015017143A (ja) | 2015-01-29 |
| JP2015017143A5 true JP2015017143A5 (https=) | 2015-07-02 |
Family
ID=41683496
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532079A Expired - Fee Related JP5643762B2 (ja) | 2008-10-15 | 2009-10-14 | 高濃度薬物粒子、製剤、懸濁液、及びこれらの使用 |
| JP2014221571A Pending JP2015017143A (ja) | 2008-10-15 | 2014-10-30 | 高濃度薬物粒子、製剤、懸濁液、及びこれらの使用 |
| JP2015100271A Pending JP2015143286A (ja) | 2008-10-15 | 2015-05-15 | 高濃度薬物粒子、製剤、懸濁液、及びこれらの使用 |
| JP2017058941A Pending JP2017119709A (ja) | 2008-10-15 | 2017-03-24 | 高濃度薬物粒子、製剤、懸濁液、及びこれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532079A Expired - Fee Related JP5643762B2 (ja) | 2008-10-15 | 2009-10-14 | 高濃度薬物粒子、製剤、懸濁液、及びこれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015100271A Pending JP2015143286A (ja) | 2008-10-15 | 2015-05-15 | 高濃度薬物粒子、製剤、懸濁液、及びこれらの使用 |
| JP2017058941A Pending JP2017119709A (ja) | 2008-10-15 | 2017-03-24 | 高濃度薬物粒子、製剤、懸濁液、及びこれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20100092566A1 (https=) |
| EP (1) | EP2349200A1 (https=) |
| JP (4) | JP5643762B2 (https=) |
| KR (1) | KR101419583B1 (https=) |
| CN (4) | CN102281865B (https=) |
| AU (1) | AU2009303905B2 (https=) |
| CA (1) | CA2738715C (https=) |
| HK (1) | HK1200332A1 (https=) |
| IL (1) | IL211948A0 (https=) |
| MX (1) | MX2011003833A (https=) |
| NZ (1) | NZ592113A (https=) |
| WO (1) | WO2010044867A1 (https=) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| KR101106510B1 (ko) | 2006-05-30 | 2012-01-20 | 인타르시아 세라퓨틱스 인코포레이티드 | 투피스, 내부채널 삼투압 전달 시스템 유동 조절기 |
| EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
| WO2008133908A2 (en) | 2007-04-23 | 2008-11-06 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
| SG187410A1 (en) | 2007-12-28 | 2013-02-28 | Baxter Int | Recombinant vwf formulations |
| US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| CN102281865B (zh) * | 2008-10-15 | 2017-04-05 | 精达制药公司 | 高浓缩药物颗粒、制剂、混悬剂及其应用 |
| RS59913B1 (sr) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
| EP2349314B1 (en) | 2008-10-21 | 2013-02-27 | Baxter International Inc. | Lyophilized recombinant vwf formulations |
| CN102596175A (zh) | 2009-07-06 | 2012-07-18 | 赛诺菲-安万特德国有限公司 | 含有甲硫氨酸的水性胰岛素制备物 |
| AU2014280920B2 (en) * | 2009-09-28 | 2016-05-12 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
| RU2547990C2 (ru) | 2009-09-28 | 2015-04-10 | Интарсия Терапьютикс, Инк. | Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства |
| MY180661A (en) | 2009-11-13 | 2020-12-04 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| PT3345593T (pt) * | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina |
| MX2012013001A (es) | 2010-05-13 | 2013-02-26 | Univ Indiana Res & Tech Corp | Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas. |
| PL2611458T3 (pl) | 2010-08-30 | 2017-02-28 | Sanofi-Aventis Deutschland Gmbh | Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2 |
| JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| US20120208755A1 (en) * | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| KR101767879B1 (ko) | 2011-07-12 | 2017-08-14 | 현대모비스 주식회사 | 전동식 동력 조향장치를 이용한 차륜 정렬장치 및 그 방법 |
| AR087693A1 (es) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| JP6324315B2 (ja) * | 2011-11-17 | 2018-05-16 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド |
| KR102143482B1 (ko) | 2011-11-30 | 2020-08-11 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 펩티드 치료제 및 아미노산을 포함하는 마이크로니들 장치, 이의 제조 및 사용 방법 |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| MX2016008979A (es) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina. |
| BR112016015851A2 (pt) | 2014-01-09 | 2017-08-08 | Sanofi Sa | Formulações farmacêuticas estabilizadas de insulina aspart |
| MX2016008978A (es) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol. |
| US10617788B2 (en) * | 2014-01-28 | 2020-04-14 | Mccoy Enterprises, Llc | Collagen permeated medical implants |
| ES3055185T3 (en) | 2014-03-28 | 2026-02-10 | Univ Duke | Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| MX392636B (es) * | 2014-10-31 | 2025-03-24 | Glaxosmithkline Ip Dev Ltd | Formulacion en polvo. |
| EP3229828B1 (en) | 2014-12-12 | 2023-04-05 | Sanofi-Aventis Deutschland GmbH | Insulin glargine/lixisenatide fixed ratio formulation |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| KR20250152679A (ko) | 2015-04-29 | 2025-10-23 | 래디어스 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
| RU2730996C2 (ru) | 2015-06-03 | 2020-08-26 | Интарсия Терапьютикс, Инк. | Системы установки и извлечения имплантата |
| KR102574993B1 (ko) | 2016-05-16 | 2023-09-06 | 인타르시아 세라퓨틱스 인코포레이티드 | 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법 |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| CN110087763A (zh) | 2016-11-22 | 2019-08-02 | 伊勒卓菲公司 | 包含治疗剂或诊断剂的颗粒和悬浮液以及其使用方法 |
| JP7286542B2 (ja) | 2017-01-03 | 2023-06-05 | インターシア セラピューティクス，インコーポレイティド | Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法 |
| JP7481115B2 (ja) | 2017-01-05 | 2024-05-10 | ラジウス ファーマシューティカルズ，インコーポレイテッド | Ｒａｄ１９０１－２ｈｃｌの多形性形態 |
| JP2018196401A (ja) * | 2017-05-19 | 2018-12-13 | ロレアル | マイクロニードルシート |
| AU2018306303A1 (en) | 2017-07-25 | 2020-02-20 | Elektrofi, Inc. | Formation of particles including agents |
| WO2019226969A1 (en) | 2018-05-24 | 2019-11-28 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| MX2020013713A (es) | 2018-07-04 | 2021-03-02 | Radius Pharmaceuticals Inc | Formas polimorficas de rad1901-2hcl. |
| USD933219S1 (en) | 2018-07-13 | 2021-10-12 | Intarcia Therapeutics, Inc. | Implant removal tool and assembly |
| US12441776B2 (en) * | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| EP3917500A2 (en) | 2019-01-31 | 2021-12-08 | Elektrofi, Inc. | Particle formation and morphology |
| CN113661006A (zh) | 2019-02-05 | 2021-11-16 | 林迪生物科学公司 | 分离的细胞培养物组分以及用于从液体细胞培养基中分离其的方法 |
| EP3924328A1 (en) | 2019-02-12 | 2021-12-22 | Radius Pharmaceuticals, Inc. | Processes and compounds |
| JP7549593B2 (ja) | 2019-03-15 | 2024-09-11 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１ペプチドを噴霧乾燥するためのプロセス |
| EP4027978A1 (en) | 2019-09-13 | 2022-07-20 | Elektrofi, Inc. | Compositions and methods for the delivery of therapeutic biologics for treatment of disease |
| WO2021212019A1 (en) | 2020-04-17 | 2021-10-21 | Elektrofi, Inc. | Methods of forming particles by continuous droplet formation and dehydration |
| JPWO2022124285A1 (https=) * | 2020-12-09 | 2022-06-16 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU225496B1 (en) * | 1993-04-07 | 2007-01-29 | Scios Inc | Pharmaceutical compositions of prolonged delivery, containing peptides |
| US6284727B1 (en) * | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5904935A (en) * | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
| US6132420A (en) * | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
| NZ331186A (en) * | 1996-02-02 | 2000-04-28 | Alza Corp | Osmotically driven sustained delivery drug delivery capsule |
| US5932547A (en) * | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
| JP4642946B2 (ja) * | 1996-12-20 | 2011-03-02 | アルザ コーポレイション | ゲル組成物および方法 |
| ZA981610B (en) * | 1997-03-24 | 1999-08-26 | Alza Corp | Self adjustable exit port. |
| MY125849A (en) * | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
| MY125870A (en) * | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system flow modulator apparatus and method |
| AU1623099A (en) * | 1997-12-22 | 1999-07-12 | Alza Corporation | Rate controlling membranes for controlled drug delivery devices |
| PT1044032E (pt) * | 1997-12-29 | 2004-08-31 | Alza Corp | Dispositivo de implantacao para implantes sebcutaneos |
| WO1999033446A1 (en) * | 1997-12-29 | 1999-07-08 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
| KR100568917B1 (ko) * | 1997-12-30 | 2006-04-07 | 알자 코포레이션 | 멤브레인 플러그를 갖는 익제 전달장치 |
| EP1140014B1 (en) * | 1998-12-31 | 2003-03-19 | Alza Corporation | Osmotic delivery system having space efficient piston |
| US7258869B1 (en) * | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| ES2248156T3 (es) * | 1999-12-21 | 2006-03-16 | Alza Corporation | Valvula para dispositivos osmoticos. |
| US7163688B2 (en) * | 2001-06-22 | 2007-01-16 | Alza Corporation | Osmotic implant with membrane and membrane retention means |
| WO2003105803A1 (en) * | 2002-06-17 | 2003-12-24 | Alza Corporation | Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle |
| DE60317225T2 (de) * | 2002-06-26 | 2008-05-29 | Intarcia Therapeutics, Inc., Emeryville | Minimal nachgiebiger volumen-effizienter kolben für osmotische medikamentenabgabesysteme |
| AU2003283004A1 (en) * | 2002-10-22 | 2004-05-13 | Waratah Pharmaceuticals, Inc. | Treatment of diabetes |
| US7014636B2 (en) * | 2002-11-21 | 2006-03-21 | Alza Corporation | Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel |
| US7731947B2 (en) * | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| MXPA05006604A (es) * | 2002-12-19 | 2006-05-25 | Alza Corp | Geles de una sola fase, no acuosos, estables, y formulaciones de los mismos para el suministro desde un aparato implantable. |
| DE602004012081T2 (de) * | 2003-03-31 | 2009-03-19 | Intarcia Therapeutics, Inc., Emeryville | Osmotische pumpe mit mitteln zum ableiten des innendrucks |
| TW200509999A (en) * | 2003-03-31 | 2005-03-16 | Alza Corp | Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
| CN1767815A (zh) * | 2003-03-31 | 2006-05-03 | 阿尔萨公司 | 非水单相载体和使用这类载体的制剂 |
| MXPA06002967A (es) * | 2003-09-30 | 2006-06-14 | Alza Corp | Aparato de suministro de agente activo de conduccion osmotica que proporciona perfil de liberacion ascendente. |
| AU2004287402A1 (en) * | 2003-10-31 | 2005-05-19 | Alza Corporation | Osmotic pump with self-retaining, fast-start membrane plug |
| PL379736A1 (pl) * | 2003-11-06 | 2006-11-13 | Alza Corporation | Modułowy reduktor prędkości wchłaniania do stosowania z wszczepianą pompą osmotyczną |
| CN1917857A (zh) * | 2004-02-10 | 2007-02-21 | 阿尔萨公司 | 防止回流进活性剂贮库的渗透性递药系统中的毛细管调节器 |
| US20050175701A1 (en) * | 2004-02-10 | 2005-08-11 | Alza Corporation | Capillary moderator for osmotic delivery system |
| US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
| US7772182B2 (en) * | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
| US20060216242A1 (en) * | 2005-02-03 | 2006-09-28 | Rohloff Catherine M | Suspending vehicles and pharmaceutical suspensions for drug dosage forms |
| US7655254B2 (en) * | 2005-02-03 | 2010-02-02 | Intarcia Therapeutics, Inc. | Implantable device for continuous delivery of interferon |
| WO2006083761A2 (en) * | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US7959938B2 (en) * | 2005-03-15 | 2011-06-14 | Intarcia Therapeutics, Inc. | Polyoxaester suspending vehicles for use with implantable delivery systems |
| US20070027105A1 (en) * | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
| KR101106510B1 (ko) * | 2006-05-30 | 2012-01-20 | 인타르시아 세라퓨틱스 인코포레이티드 | 투피스, 내부채널 삼투압 전달 시스템 유동 조절기 |
| EP2359808B1 (en) * | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
| WO2008133908A2 (en) * | 2007-04-23 | 2008-11-06 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
| JP2011506442A (ja) * | 2007-12-11 | 2011-03-03 | コンジュケム バイオテクノロジーズ インコーポレイテッド | インスリン分泌性ペプチド結合体の製剤 |
| CA2726861C (en) * | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| CN102281865B (zh) * | 2008-10-15 | 2017-04-05 | 精达制药公司 | 高浓缩药物颗粒、制剂、混悬剂及其应用 |
| JP5464610B2 (ja) * | 2009-06-05 | 2014-04-09 | ジェ ファ チン | パーマ液第１剤 |
-
2009
- 2009-10-14 CN CN200980140859.XA patent/CN102281865B/zh not_active Expired - Fee Related
- 2009-10-14 CN CN201710129813.4A patent/CN106880596A/zh active Pending
- 2009-10-14 US US12/587,946 patent/US20100092566A1/en not_active Abandoned
- 2009-10-14 JP JP2011532079A patent/JP5643762B2/ja not_active Expired - Fee Related
- 2009-10-14 AU AU2009303905A patent/AU2009303905B2/en not_active Ceased
- 2009-10-14 KR KR1020117008047A patent/KR101419583B1/ko not_active Expired - Fee Related
- 2009-10-14 MX MX2011003833A patent/MX2011003833A/es unknown
- 2009-10-14 NZ NZ592113A patent/NZ592113A/en not_active IP Right Cessation
- 2009-10-14 CN CN201410277361.0A patent/CN104013569A/zh active Pending
- 2009-10-14 WO PCT/US2009/005629 patent/WO2010044867A1/en not_active Ceased
- 2009-10-14 CA CA2738715A patent/CA2738715C/en active Active
- 2009-10-14 EP EP09741052A patent/EP2349200A1/en not_active Ceased
- 2009-10-14 CN CN201611114204.3A patent/CN106539756A/zh active Pending
-
2011
- 2011-03-27 IL IL211948A patent/IL211948A0/en unknown
-
2012
- 2012-07-07 US US13/543,821 patent/US20120289944A1/en not_active Abandoned
-
2014
- 2014-10-30 JP JP2014221571A patent/JP2015017143A/ja active Pending
-
2015
- 2015-01-23 HK HK15100800.3A patent/HK1200332A1/xx unknown
- 2015-05-15 JP JP2015100271A patent/JP2015143286A/ja active Pending
- 2015-10-08 US US14/878,144 patent/US20160022582A1/en not_active Abandoned
-
2017
- 2017-01-17 US US15/408,112 patent/US20170119854A1/en not_active Abandoned
- 2017-03-24 JP JP2017058941A patent/JP2017119709A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015017143A5 (https=) | ||
| CN104080506B (zh) | 包含肽治疗剂和氨基酸的微针装置以及制备和使用其的方法 | |
| US10159714B2 (en) | Compositions, devices and methods of use thereof for the treatment of cancers | |
| JP5718925B2 (ja) | 実質的な定常状態薬物送達の迅速な確立及び／又は停止 | |
| CN107072955B (zh) | 包含多肽和/或蛋白质的固体块的药物组合物和该固体块的制备方法 | |
| CA2683610A1 (en) | Suspension formulations of insulinotropic peptides and uses thereof | |
| JP5135428B2 (ja) | エキセンジン含有徐放性製剤組成物、エキセンジン含有徐放性微粒球、及びその製造方法 | |
| EP2672986B1 (en) | Lyophilized formulations | |
| US20180256492A1 (en) | Devices, formulations, and methods for delivery of multiple beneficial agents | |
| WO2019023392A1 (en) | FORMATION OF PARTICLES COMPRISING AGENTS | |
| MX2011003833A (es) | Particulas de farmacos altamente concentradas, formulaciones, suspensiones y uso de las mismas. | |
| NZ551258A (en) | A biomolecule-containing formulation of increased stability | |
| CN105899190A (zh) | 门冬胰岛素的稳定化药物制剂 | |
| WO2015140175A9 (en) | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
| JP2023022124A (ja) | インターフェロンの送達のためのマイクロニードルシステム | |
| JP2008509746A (ja) | ナトリウム利尿ペプチドを経皮送達する器具および方法 | |
| EP3534974A2 (en) | Dissolvable films and methods of their use | |
| CN115518151B (zh) | 一种人类免疫缺陷病毒中和抗体制剂及其用途 | |
| IL275674B1 (en) | Method for producing a drug delivery system | |
| CN119095618A (zh) | 用于治疗巨噬细胞活化综合征的组合物和方法 | |
| NZ739899A (en) | Biopharmaceutical compositions | |
| JP2016040307A5 (https=) |